Revenue from Contract with Customer, Excluding Assessed Tax of Zenas BioPharma, Inc. from 30 Sep 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Zenas BioPharma, Inc. annual and quarterly Revenue from Contract with Customer, Excluding Assessed Tax in USD history and change rate from 30 Sep 2023 to 31 Dec 2025.
  • Zenas BioPharma, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 31 Mar 2025 was $10,000,000.
  • Zenas BioPharma, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2025 was $10,000,000, a 100% increase from 2024.
  • Zenas BioPharma, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2024 was $5,000,000, a 90% decline from 2023.
Source SEC data
View on sec.gov
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)

Zenas BioPharma, Inc. Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $10,000,000 +$5,000,000 +100% 01 Jan 2025 31 Dec 2025 10-K 16 Mar 2026 2025 FY
2024 $5,000,000 -$45,000,000 -90% 01 Jan 2024 31 Dec 2024 10-K 16 Mar 2026 2025 FY
2023 $50,000,000 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY

Zenas BioPharma, Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $10,000,000 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q3 2023 $50,000,000 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.